Followers | 261 |
Posts | 19732 |
Boards Moderated | 0 |
Alias Born | 10/03/2004 |
Tuesday, January 26, 2021 1:40:24 AM
Not unusual. Yes, including the time for Polymedix prior to IPIX, B has been in development for 15 years. When there is no urgent need, or there’s been no government focus, vaccines and therapeutics can take decades.
The current spate of mRNA vaccines have been in development for more than 30 years. If it weren’t for a pandemic Big Pharma was probably at least 5 years or more away from consideration of approval. More importantly, last March the Covid task force prioritized vaccines over therapeutics. Lots of money for vaccines, almost none for therapeutics.
Now that there are vaccines, the focus will turn to therapies for those the vaccines have yet to reach. At 1.5 million doses a day, the US is still at least 6 months from herd immunity. Moreover, there is still a month or two lag period to get the next 100 million doses manufactured and distributed.
Therapeutic use for Brilacidin is now becoming urgent as deaths are 4 to 8 weeks behind infections. If B works, it will likely reduce time of infection, tissue damage and recovery time. We should all pray that Covid victims see immediate relief beginning with patient 1. Patient 1 is anticipated by end of next week if the trial begins this week as PRed.
* Never borrow to invest.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM